Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis.
Gourdy P, Bonadonna RC, Mauricio D, Müller-Wieland D, Mauquoi C, Vera C, Bonnemaire M, Freemantle N. Gourdy P, et al. Among authors: muller wieland d. Diabetes Obes Metab. 2025 Jan;27(1):228-237. doi: 10.1111/dom.16008. Epub 2024 Oct 17. Diabetes Obes Metab. 2025. PMID: 39420531 Free PMC article.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Haluzík M, Cheng A, Müller-Wieland D, Westerbacka J, Bosnyak Z, Lauand F, Melas-Melt L, Karalliedde J, Rosenstock J, Bolli GB. Haluzík M, et al. Diabetes Obes Metab. 2020 Aug;22(8):1369-1377. doi: 10.1111/dom.14043. Epub 2020 Apr 28. Diabetes Obes Metab. 2020. PMID: 32243043 Free PMC article. Clinical Trial.
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR. Leiter LA, et al. Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114. Epub 2017 Oct 10. Diabetes Obes Metab. 2017. PMID: 28905478 Free PMC article. Clinical Trial.
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S. Ray KK, et al. Diabetes Obes Metab. 2018 Jun;20(6):1479-1489. doi: 10.1111/dom.13257. Epub 2018 Mar 23. Diabetes Obes Metab. 2018. PMID: 29436756 Free PMC article. Clinical Trial.
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Letierce A, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Cariou B, et al. Diabetes Metab. 2017 Oct;43(5):453-459. doi: 10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24. Diabetes Metab. 2017. PMID: 28347654 Free article. Clinical Trial.
234 results